08:30 AM EDT, 05/09/2024 (MT Newswires) -- Novo Nordisk A/S ( NVO ) could pay up to $600 million as part of a deal struck with Metaphore Biotechnologies and Flagship Pioneering to develop up to two new therapeutics for obesity management, according to a press release.

Under the terms of the agreement, the $600 million will go toward upfront, development, and commercial milestone payments, as well as tiered royalties on annual net sales of licensed products, to be shared between Metaphore and Pioneering Medicines.

Price: 127.19, Change: +0.50, Percent Change: +0.39